Insmed Inc Company Profile
What is the competitive landscape for INSMED INC
INSMED INC has two approved drugs.
There are twenty-eight US patents protecting INSMED INC drugs.
Summary for Insmed Inc
| US Patents: | 28 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Insmed Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insmed Inc | BRINSUPRI | brensocatib | TABLET;ORAL | 217673-002 | Aug 12, 2025 | RX | Yes | Yes | 12,054,465 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Insmed Inc | BRINSUPRI | brensocatib | TABLET;ORAL | 217673-002 | Aug 12, 2025 | RX | Yes | Yes | 11,673,871 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Insmed Inc | BRINSUPRI | brensocatib | TABLET;ORAL | 217673-001 | Aug 12, 2025 | RX | Yes | No | 9,815,805 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Insmed Inc | BRINSUPRI | brensocatib | TABLET;ORAL | 217673-001 | Aug 12, 2025 | RX | Yes | No | 11,655,224 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Insmed Inc | ARIKAYCE KIT | amikacin sulfate | SUSPENSION, LIPOSOMAL;INHALATION | 207356-001 | Sep 28, 2018 | RX | Yes | Yes | 12,168,021 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Insmed Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Insmed Inc | ARIKAYCE KIT | amikacin sulfate | SUSPENSION, LIPOSOMAL;INHALATION | 207356-001 | Sep 28, 2018 | 7,718,189 | ⤷ Start Trial |
| Insmed Inc | ARIKAYCE KIT | amikacin sulfate | SUSPENSION, LIPOSOMAL;INHALATION | 207356-001 | Sep 28, 2018 | 9,827,317 | ⤷ Start Trial |
| Insmed Inc | ARIKAYCE KIT | amikacin sulfate | SUSPENSION, LIPOSOMAL;INHALATION | 207356-001 | Sep 28, 2018 | 8,802,137 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Insmed Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| San Marino | T202500137 | ⤷ Start Trial |
| Cyprus | 1122129 | ⤷ Start Trial |
| South Korea | 102489036 | ⤷ Start Trial |
| Mexico | 2016014921 | ⤷ Start Trial |
| Hungary | E051440 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Insmed Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3097086 | CR 2026 00019 | Denmark | ⤷ Start Trial | PRODUCT NAME: BRENSOCATIB ELLER FARMACEUTISK ACCEPTABLE SALTE HERAF, HYDRATER, ELLER HYDRATER AF SALTENE, HERUNDER BRENSOCATIBMONOHYDRAT; REG. NO/DATE: EU/1/25/1995 20251119 |
| 3097086 | CA 2026 00019 | Denmark | ⤷ Start Trial | PRODUCT NAME: BRENSOCATIB OG SALTE HERAF, HYDRATER, ELLER HYDRATER AF SALTENE, HERUNDER BRENSOCATIB MONOHYDRAT; REG. NO/DATE: EU/1/25/1995 20251119 |
| 3097086 | 301376 | Netherlands | ⤷ Start Trial | PRODUCT NAME: BRENSOCATIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/25/1995/001 20251119 |
| 3097086 | LUC50047 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: BRENSOCATIB OU SES SELS, SES HYDRATES OU LES HYDRATES DE SES SELS, Y COMPRIS LE BRENSOCATIB MONOHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/25/1995/001 20251119 |
| 3097086 | 2/2026 | Austria | ⤷ Start Trial | PRODUCT NAME: BRENSOCATIB ODER SEINE SALZE, HYDRATE, ODER HYDRATE DER SALZE, BEINHALTEND BRENSOCATIB MONOHYDRAT; REGISTRATION NO/DATE: EU/1/25/1995 (MITTEILUNG) 20251119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
